Dermira Inc. Chief Commercial Officer Lori Lyons-Williams said the company has been pursuing reimbursement since January for Qbrexza (glycopyrronium), approved in the US for primary axillary hyperhidrosis (excessive underarm sweating) at the end of June, and found that having patients share their experiences with skeptical payers has been the most effective strategy for obtaining coverage.
Dermira Leans On Patient Experience With Hyperhidrosis As It Readies For Qbrexza Launch
Chief Commercial Officer Lori Lyons-Williams tells Scrip that patient stories were the tipping point for many payers considering Qbrexza's $550 per month price. Dermira's also catering to patients with co-pay assistance and a commitment not to raise pricing until after 2019.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.